Rimonabant or Acomplia is an
anorectic anti-obesity drug.

It will be sold by Sanofi-Aventis under the trade name Acomplia starting in 2006. Rimonabant might also be effective as an anti-addictive drug in the treatment of alcoholism as well as nicotine and stimulant addiction. Rimonabant is a CB1 cannabinoid receptor antagonist.

Early results of two Phase III studies with ACOMPLIA? (rimonabant), the first in a new class of therapeutics called Selective CB1 Blockers, indicate that overweight/obese patients with untreated dyslipidemia (high triglycerides and/or high total cholesterol/HDL cholesterol ratio) lost weight in one year while improving their lipid and glucose profiles, and that smokers who had previously unsuccessfully tried to quit smoking, were able to quit in 10 weeks without post cessation weight gain. The results of both the RIO-Lipids (Rimonabant In Obesity) and STRATUS-US (Studies with Rimonabant And Tobacco Use) trials were presented for the first time to the scientific community at the American College of Cardiology annual meeting in New Orleans, LA.
 

Primal Defense Probiotic Info | HairTransplant